195 related articles for article (PubMed ID: 30422351)
1. Defining the in vivo characteristics of acute myeloid leukemia cells behavior by intravital imaging.
Duarte D; Amarteifio S; Ang H; Kong IY; Ruivo N; Pruessner G; Hawkins ED; Lo Celso C
Immunol Cell Biol; 2019 Feb; 97(2):229-235. PubMed ID: 30422351
[TBL] [Abstract][Full Text] [Related]
2. TGF-β-Neutralizing Antibody 1D11 Enhances Cytarabine-Induced Apoptosis in AML Cells in the Bone Marrow Microenvironment.
Tabe Y; Shi YX; Zeng Z; Jin L; Shikami M; Hatanaka Y; Miida T; Hsu FJ; Andreeff M; Konopleva M
PLoS One; 2013; 8(6):e62785. PubMed ID: 23826077
[TBL] [Abstract][Full Text] [Related]
3. Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia.
Ladikou EE; Chevassut T; Pepper CJ; Pepper AG
Br J Haematol; 2020 Jun; 189(5):815-825. PubMed ID: 32135579
[TBL] [Abstract][Full Text] [Related]
4. Dynamic chemotherapy-induced upregulation of CXCR4 expression: a mechanism of therapeutic resistance in pediatric AML.
Sison EA; McIntyre E; Magoon D; Brown P
Mol Cancer Res; 2013 Sep; 11(9):1004-16. PubMed ID: 23754844
[TBL] [Abstract][Full Text] [Related]
5. Improving chemotherapeutic efficiency in acute myeloid leukemia treatments by chemically synthesized peptide interfering with CXCR4/CXCL12 axis.
Li X; Guo H; Duan H; Yang Y; Meng J; Liu J; Wang C; Xu H
Sci Rep; 2015 Nov; 5():16228. PubMed ID: 26538086
[TBL] [Abstract][Full Text] [Related]
6. Role of CXCR4 in the pathogenesis of acute myeloid leukemia.
Peled A; Tavor S
Theranostics; 2013; 3(1):34-9. PubMed ID: 23382784
[TBL] [Abstract][Full Text] [Related]
7. CXCR4 Signaling Has a CXCL12-Independent Essential Role in Murine MLL-AF9-Driven Acute Myeloid Leukemia.
Ramakrishnan R; Peña-Martínez P; Agarwal P; Rodriguez-Zabala M; Chapellier M; Högberg C; Eriksson M; Yudovich D; Shah M; Ehinger M; Nilsson B; Larsson J; Hagström-Andersson A; Ebert BL; Bhatia R; Järås M
Cell Rep; 2020 May; 31(8):107684. PubMed ID: 32460032
[TBL] [Abstract][Full Text] [Related]
8. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML.
Zeng Z; Shi YX; Samudio IJ; Wang RY; Ling X; Frolova O; Levis M; Rubin JB; Negrin RR; Estey EH; Konoplev S; Andreeff M; Konopleva M
Blood; 2009 Jun; 113(24):6215-24. PubMed ID: 18955566
[TBL] [Abstract][Full Text] [Related]
9. Intravital Microscopy to Study the Effect of Matrix Metalloproteinase Inhibition on Acute Myeloid Leukemia Cell Migration in the Bone Marrow.
Tissot FS; Gonzalez-Anton S; Lo Celso C
Methods Mol Biol; 2024; 2747():211-227. PubMed ID: 38038943
[TBL] [Abstract][Full Text] [Related]
10. TGF-β1 and CXCL12 modulate proliferation and chemotherapy sensitivity of acute myeloid leukemia cells co-cultured with multipotent mesenchymal stromal cells.
Schelker RC; Iberl S; Müller G; Hart C; Herr W; Grassinger J
Hematology; 2018 Jul; 23(6):337-345. PubMed ID: 29140182
[TBL] [Abstract][Full Text] [Related]
11. Blocking migration of regulatory T cells to leukemic hematopoietic microenvironment delays disease progression in mouse leukemia model.
Wang R; Feng W; Wang H; Wang L; Yang X; Yang F; Zhang Y; Liu X; Zhang D; Ren Q; Feng X; Zheng G
Cancer Lett; 2020 Jan; 469():151-161. PubMed ID: 31669202
[TBL] [Abstract][Full Text] [Related]
12. CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice.
Tavor S; Petit I; Porozov S; Avigdor A; Dar A; Leider-Trejo L; Shemtov N; Deutsch V; Naparstek E; Nagler A; Lapidot T
Cancer Res; 2004 Apr; 64(8):2817-24. PubMed ID: 15087398
[TBL] [Abstract][Full Text] [Related]
13. CXCR4 inhibitors selectively eliminate CXCR4-expressing human acute myeloid leukemia cells in NOG mouse model.
Zhang Y; Patel S; Abdelouahab H; Wittner M; Willekens C; Shen S; Betems A; Joulin V; Opolon P; Bawa O; Pasquier F; Ito M; Fujii N; Gonin P; Solary E; Vainchenker W; Coppo P; De Botton S; Louache F
Cell Death Dis; 2012 Oct; 3(10):e396. PubMed ID: 23034331
[TBL] [Abstract][Full Text] [Related]
14. A designed peptide targeting CXCR4 displays anti-acute myelocytic leukemia activity in vitro and in vivo.
Li X; Guo H; Yang Y; Meng J; Liu J; Wang C; Xu H
Sci Rep; 2014 Oct; 4():6610. PubMed ID: 25312253
[TBL] [Abstract][Full Text] [Related]
15. The CXCR4 antagonist AMD3100 impairs survival of human AML cells and induces their differentiation.
Tavor S; Eisenbach M; Jacob-Hirsch J; Golan T; Petit I; Benzion K; Kay S; Baron S; Amariglio N; Deutsch V; Naparstek E; Rechavi G
Leukemia; 2008 Dec; 22(12):2151-5158. PubMed ID: 18769446
[TBL] [Abstract][Full Text] [Related]
16. A CXCR4 antagonist leads to tumor suppression by activation of immune cells in a leukemia-induced microenvironment.
Han AR; Lee JY; Kim HJ; Min WS; Park G; Kim SH
Oncol Rep; 2015 Dec; 34(6):2880-8. PubMed ID: 26398122
[TBL] [Abstract][Full Text] [Related]
17. AMD3100 and G-CSF disrupt the cross-talk between leukemia cells and the endosteal niche and enhance their sensitivity to chemotherapeutic drugs in biomimetic polystyrene scaffolds.
Shen ZH; Zeng DF; Kong PY; Ma YY; Zhang X
Blood Cells Mol Dis; 2016 Jul; 59():16-24. PubMed ID: 27282562
[TBL] [Abstract][Full Text] [Related]
18. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
[TBL] [Abstract][Full Text] [Related]
19. Dual blockade of CXCL12-CXCR4 and PD-1-PD-L1 pathways prolongs survival of ovarian tumor-bearing mice by prevention of immunosuppression in the tumor microenvironment.
Zeng Y; Li B; Liang Y; Reeves PM; Qu X; Ran C; Liu Q; Callahan MV; Sluder AE; Gelfand JA; Chen H; Poznansky MC
FASEB J; 2019 May; 33(5):6596-6608. PubMed ID: 30802149
[TBL] [Abstract][Full Text] [Related]
20. Plerixafor as a chemosensitizing agent in pediatric acute lymphoblastic leukemia: efficacy and potential mechanisms of resistance to CXCR4 inhibition.
Sison EA; Magoon D; Li L; Annesley CE; Rau RE; Small D; Brown P
Oncotarget; 2014 Oct; 5(19):8947-58. PubMed ID: 25333254
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]